CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,491,115
- in 20 filings, $14.5M under 10b5-1 plans
Net −$33,491,115. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-09-29 | ROBINS CHAD M CEO and Chairman | Option exercise | +1,900 | $0.33 | $627 | 1,780,080 |
| 2020-09-29 | ROBINS CHAD M CEO and Chairman | Sale | −1,900 | $50.18 | $95K | 1,778,180 |
| 2020-09-29 | ROBINS CHAD M CEO and Chairman | Option exercise · Stock Option (Right to Buy) | −1,900 | 192,740 | ||
| 2020-09-29 | BALDO LANCE Chief Medical Officer | Option exercise | +25,000 | $7.80 | $195K | 25,000 |
| 2020-09-29 | BALDO LANCE Chief Medical Officer | Sale | −25,000 | $50.00 | $1.3M | 0 |
| 2020-09-29 | BALDO LANCE Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −25,000 | 400,000 | ||
| 2020-09-29 | BOBULSKY SUSAN SVP, Diagnostics, clonoSEQ | Option exercise | +10,000 | $1.98 | $20K | 10,000 |
| 2020-09-29 | BOBULSKY SUSAN SVP, Diagnostics, clonoSEQ | Sale | −10,000 | $50.00 | $500K | 0 |
| 2020-09-29 | BOBULSKY SUSAN SVP, Diagnostics, clonoSEQ | Option exercise · Stock Option (Right to Buy) | −10,000 | 55,000 | ||
| 2020-09-24 | Taylor Stacy L SVP and General Counsel | Option exercise | +1,109 | $7.80 | $9K | 2,409 |
| 2020-09-24 | Taylor Stacy L SVP and General Counsel | Option exercise | +1,771 | $6.55 | $12K | 4,180 |
| 2020-09-24 | Taylor Stacy L SVP and General Counsel | Sale | −2,284 | $47.59 | $109K | 1,896 |
| 2020-09-24 | Taylor Stacy L SVP and General Counsel | Sale | −596 | $48.49 | $29K | 1,300 |
| 2020-09-24 | Taylor Stacy L SVP and General Counsel | Option exercise · Stock Option (Right to Buy) | −1,109 | 36,145 | ||
| 2020-09-24 | Taylor Stacy L SVP and General Counsel | Option exercise · Stock Option (Right to Buy) | −1,771 | 31,875 | ||
| 2020-09-24 | ROBINS HARLAN S Chief Scientific Officer | Option exercise | +11,100 | $6.32 | $70K | 11,779 |
| 2020-09-24 | ROBINS HARLAN S Chief Scientific Officer | Sale | −3,640 | $46.00 | $167K | 8,139 |
| 2020-09-24 | ROBINS HARLAN S Chief Scientific Officer | Sale | −3,560 | $47.28 | $168K | 4,579 |
| 2020-09-24 | ROBINS HARLAN S Chief Scientific Officer | Sale | −3,900 | $47.98 | $187K | 679 |
| 2020-09-24 | ROBINS HARLAN S Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −11,100 | 300,300 |
Page 89 of 120 · 2,386 trades